These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

294 related articles for article (PubMed ID: 32366854)

  • 1. Novel Combinatorial Regimen of Garcinol and Curcuminoids for Non-alcoholic Steatohepatitis (NASH) in Mice.
    Majeed M; Majeed S; Nagabhushanam K; Lawrence L; Mundkur L
    Sci Rep; 2020 May; 10(1):7440. PubMed ID: 32366854
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The protective effects of Ninjin'yoeito against liver steatosis/fibrosis in a non-alcoholic steatohepatitis model mouse.
    Takano K; Kaneda M; Aoki Y; Fujita N; Chiba S; Michihara S; Han LK; Takahashi R
    J Nat Med; 2024 Jun; 78(3):514-524. PubMed ID: 38498120
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pan-caspase inhibitor VX-166 reduces fibrosis in an animal model of nonalcoholic steatohepatitis.
    Witek RP; Stone WC; Karaca FG; Syn WK; Pereira TA; Agboola KM; Omenetti A; Jung Y; Teaberry V; Choi SS; Guy CD; Pollard J; Charlton P; Diehl AM
    Hepatology; 2009 Nov; 50(5):1421-30. PubMed ID: 19676126
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Acetyl-CoA carboxylase inhibition disrupts metabolic reprogramming during hepatic stellate cell activation.
    Bates J; Vijayakumar A; Ghoshal S; Marchand B; Yi S; Kornyeyev D; Zagorska A; Hollenback D; Walker K; Liu K; Pendem S; Newstrom D; Brockett R; Mikaelian I; Kusam S; Ramirez R; Lopez D; Li L; Fuchs BC; Breckenridge DG
    J Hepatol; 2020 Oct; 73(4):896-905. PubMed ID: 32376414
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Thrombospondin-I is a critical modulator in non-alcoholic steatohepatitis (NASH).
    Min-DeBartolo J; Schlerman F; Akare S; Wang J; McMahon J; Zhan Y; Syed J; He W; Zhang B; Martinez RV
    PLoS One; 2019; 14(12):e0226854. PubMed ID: 31891606
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel oral SPT inhibitor CH5169356 inhibits hepatic stellate cell activation and ameliorates hepatic fibrosis in mouse models of non-alcoholic steatohepatitis (NASH).
    Hada N; Katsume A; Kenichi K; Endo C; Horiba N; Sudoh M
    Pharmacol Res Perspect; 2023 Jun; 11(3):e01094. PubMed ID: 37204099
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapeutic effects of angiotensin II type 1 receptor blocker, irbesartan, on non-alcoholic steatohepatitis using FLS-ob/ob male mice.
    Kato J; Koda M; Kishina M; Tokunaga S; Matono T; Sugihara T; Ueki M; Murawaki Y
    Int J Mol Med; 2012 Jul; 30(1):107-13. PubMed ID: 22469867
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Progression of non-alcoholic steatosis to steatohepatitis and fibrosis parallels cumulative accumulation of danger signals that promote inflammation and liver tumors in a high fat-cholesterol-sugar diet model in mice.
    Ganz M; Bukong TN; Csak T; Saha B; Park JK; Ambade A; Kodys K; Szabo G
    J Transl Med; 2015 Jun; 13():193. PubMed ID: 26077675
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cyclooxygenase-2 expression in hepatocytes attenuates non-alcoholic steatohepatitis and liver fibrosis in mice.
    Motiño O; Agra N; Brea Contreras R; Domínguez-Moreno M; García-Monzón C; Vargas-Castrillón J; Carnovale CE; Boscá L; Casado M; Mayoral R; Valdecantos MP; Valverde ÁM; Francés DE; Martín-Sanz P
    Biochim Biophys Acta; 2016 Sep; 1862(9):1710-23. PubMed ID: 27321932
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Astaxanthin Prevents Diet-Induced NASH Progression by Shaping Intrahepatic Immunity.
    Yang M; Kimchi ET; Staveley-O'Carroll KF; Li G
    Int J Mol Sci; 2021 Oct; 22(20):. PubMed ID: 34681695
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fucoxanthin inhibits hepatic oxidative stress, inflammation, and fibrosis in diet-induced nonalcoholic steatohepatitis model mice.
    Takatani N; Kono Y; Beppu F; Okamatsu-Ogura Y; Yamano Y; Miyashita K; Hosokawa M
    Biochem Biophys Res Commun; 2020 Jul; 528(2):305-310. PubMed ID: 32475638
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A high-fat diet and multiple administration of carbon tetrachloride induces liver injury and pathological features associated with non-alcoholic steatohepatitis in mice.
    Kubota N; Kado S; Kano M; Masuoka N; Nagata Y; Kobayashi T; Miyazaki K; Ishikawa F
    Clin Exp Pharmacol Physiol; 2013 Jul; 40(7):422-30. PubMed ID: 23611112
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aerobic exercise training in the treatment of non-alcoholic fatty liver disease related fibrosis.
    Linden MA; Sheldon RD; Meers GM; Ortinau LC; Morris EM; Booth FW; Kanaley JA; Vieira-Potter VJ; Sowers JR; Ibdah JA; Thyfault JP; Laughlin MH; Rector RS
    J Physiol; 2016 Sep; 594(18):5271-84. PubMed ID: 27104887
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epigallocatechin gallate attenuated non-alcoholic steatohepatitis induced by methionine- and choline-deficient diet.
    Ding Y; Sun X; Chen Y; Deng Y; Qian K
    Eur J Pharmacol; 2015 Aug; 761():405-12. PubMed ID: 25967348
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Imaging Fibrogenesis in a Diet-Induced Model of Nonalcoholic Steatohepatitis (NASH).
    Hartimath SV; Boominathan R; Soh V; Cheng P; Deng X; Chong YC; Yong FF; Tan PW; Han W; Robins EG; Goggi JL
    Contrast Media Mol Imaging; 2019; 2019():6298128. PubMed ID: 31866798
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Calycosin attenuates triglyceride accumulation and hepatic fibrosis in murine model of non-alcoholic steatohepatitis via activating farnesoid X receptor.
    Duan X; Meng Q; Wang C; Liu Z; Liu Q; Sun H; Sun P; Yang X; Huo X; Peng J; Liu K
    Phytomedicine; 2017 Feb; 25():83-92. PubMed ID: 28190475
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CD44 is a key player in non-alcoholic steatohepatitis.
    Patouraux S; Rousseau D; Bonnafous S; Lebeaupin C; Luci C; Canivet CM; Schneck AS; Bertola A; Saint-Paul MC; Iannelli A; Gugenheim J; Anty R; Tran A; Bailly-Maitre B; Gual P
    J Hepatol; 2017 Aug; 67(2):328-338. PubMed ID: 28323124
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vitronectin deficiency attenuates hepatic fibrosis in a non-alcoholic steatohepatitis-induced mouse model.
    Hayashida M; Hashimoto K; Ishikawa T; Miyamoto Y
    Int J Exp Pathol; 2019 Apr; 100(2):72-82. PubMed ID: 30887659
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Selective Acetyl-CoA Carboxylase 1 Inhibitor Improves Hepatic Steatosis and Hepatic Fibrosis in a Preclinical Nonalcoholic Steatohepatitis Model.
    Tamura YO; Sugama J; Iwasaki S; Sasaki M; Yasuno H; Aoyama K; Watanabe M; Erion DM; Yashiro H
    J Pharmacol Exp Ther; 2021 Nov; 379(3):280-289. PubMed ID: 34535562
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The soluble guanylate cyclase stimulator IW-1973 prevents inflammation and fibrosis in experimental non-alcoholic steatohepatitis.
    Flores-Costa R; Alcaraz-Quiles J; Titos E; López-Vicario C; Casulleras M; Duran-Güell M; Rius B; Diaz A; Hall K; Shea C; Sarno R; Currie M; Masferrer JL; Clària J
    Br J Pharmacol; 2018 Mar; 175(6):953-967. PubMed ID: 29281143
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.